RecruitingNCT07124000
DESTINY-PANTUMOUR04
Studying Carcinoma of esophagus, salivary gland type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Intervention
- Trastuzumab deruxtecan(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18-130 years · All sexes
- Timeline
- 2025 – 2028
Study locations (15)
- Research Site, Birmingham, Alabama, United States
- Research Site, Casa Grande, Arizona, United States
- Research Site, San Diego, California, United States
- Research Site, Aurora, Colorado, United States
- Research Site, Coral Springs, Florida, United States
- Research Site, Fort Myers, Florida, United States
- Research Site, Palm Harbor, Florida, United States
- Research Site, O'Fallon, Illinois, United States
- Research Site, Durham, North Carolina, United States
- Research Site, Wilson, North Carolina, United States
- Research Site, Canton, Ohio, United States
- Research Site, Maumee, Ohio, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Chattanooga, Tennessee, United States
- Research Site, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07124000 on ClinicalTrials.govOther trials for Carcinoma of esophagus, salivary gland type
Additional recruiting or active studies for the same condition.
See all trials for Carcinoma of esophagus, salivary gland type →